- Home
- FBP vs VRNA Comparison
FBP vs VRNA Comparison
Compare FBP & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBP
- VRNA
- Stock Information
- Founded
- FBP 1948
- VRNA 2005
- Country
- FBP United States
- VRNA United Kingdom
- Employees
- FBP N/A
- VRNA N/A
- Industry
- FBP Major Banks
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- FBP Finance
- VRNA Health Care
- Exchange
- FBP Nasdaq
- VRNA Nasdaq
- Market Cap
- FBP 3.2B
- VRNA 3.4B
- IPO Year
- FBP N/A
- VRNA 2017
- Fundamental
- Price
- FBP $19.68
- VRNA $53.30
- Analyst Decision
- FBP Buy
- VRNA Strong Buy
- Analyst Count
- FBP 4
- VRNA 7
- Target Price
- FBP $21.75
- VRNA $53.14
- AVG Volume (30 Days)
- FBP 1.1M
- VRNA 1.4M
- Earning Date
- FBP 01-23-2025
- VRNA 02-27-2025
- Dividend Yield
- FBP 3.23%
- VRNA N/A
- EPS Growth
- FBP 9.82
- VRNA N/A
- EPS
- FBP 1.81
- VRNA N/A
- Revenue
- FBP $868,818,000.00
- VRNA $5,624,000.00
- Revenue This Year
- FBP N/A
- VRNA N/A
- Revenue Next Year
- FBP $8.58
- VRNA $568.20
- P/E Ratio
- FBP $10.90
- VRNA N/A
- Revenue Growth
- FBP N/A
- VRNA 1127.95
- 52 Week Low
- FBP $15.85
- VRNA $11.39
- 52 Week High
- FBP $22.40
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- FBP 57.48
- VRNA 64.77
- Support Level
- FBP $17.95
- VRNA $43.44
- Resistance Level
- FBP $19.83
- VRNA $55.42
- Average True Range (ATR)
- FBP 0.45
- VRNA 3.35
- MACD
- FBP 0.21
- VRNA 0.40
- Stochastic Oscillator
- FBP 84.18
- VRNA 73.19
About FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.